News
The U.S. FDA ordered a pause on clinical trials of a combination therapy for HIV. This won't affect the company's other HIV ...
From parades to parties and everything in between, this guide has all the details you need to show your pride this June. 👇 #bham #pride #June #fun #events #downtownbham GH ...
Gilead Sciences, Inc. ( NASDAQ: GILD) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division ...
The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...
Analysts at Citi said that while the clinical hold impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously expected around 2029/2030, they believe the setback is minor, as it ...
Elon Musk's internet service Starlink has made an application to operate a satellite connection in southwestern Switzerland, ...
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
A new injection to prevent HIV is expected to be approved by the US Food and Drug Administration (FDA) later this month.
Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) declined 4% on Tuesday after the company announced that the FDA placed clinical holds on studies of several of its HIV drugs.
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results